Dr. Ho is the Vice President of Medicinal Chemistry in Athos Therapeutics Inc. He is leading all medicinal and synthetic chemistry efforts and is developing an innovative small molecule chemistry platform based on computational structural and synthetic chemistry methodologies. He previously worked at NantBioscience as a Senior Scientist and led the KRAS inhibitor and Antibody-Drug Conjugate synthesis programs. Prior to the company spin-out, it was known as Celgene/Abraxis Bioscience where he begins his career as a research scientist working on development of novel kinases and hedgehog inhibitors. He earned his BSc in Biochemistry and M.Sc. in Chemistry from at California State University of Los Angeles. He obtained his Ph.D. in Organic Chemistry from UCLA Chemistry & Biochemistry Department, working in Professor Michael Jung’s laboratory. David has worked across all stages of preclinical and clinical drug development.
